Labeler · US market

Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc. is a US drug labeler with US FDA registrations covering 2 drug concepts (2 currently active) across 4 packages. It is currently the only active US supplier of 2 drugs.

ACTIVE — US

openFDA · updated weekly

Labeler codes72426

Active drugs2

Registrations2 active / 2

Packages4

Sole supplier of2 drugs

Portfolio2 drugs · US

Every drug concept this labeler has US registrations for, by package count.

Drug	Type	NDCs	Packages	Status
Bempedoic Acid tablet, film coated	rx	1	2	SUPPLYING
Bempedoic Acid And Ezetimibe tablet, film coated	rx	1	2	SUPPLYING

Sole US supplier

Drugs where this labeler is currently the only active US supplier — a single point of failure if it exits.

At a glance

TypeLabeler
Labeler codes72426
Filing names1
Drugs (active)2
Drugs (all time)2
US registrations2
Packages4

Recent events

Shortages, recalls, and registration changes across all filing names.

Mar 27, 2024
RECALLRecall (Class III): NEXLIZET (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg, 30-count bottle, Rx only, Manufactured for: Esperion The…
Aug 16, 2023
RECALLRecall (Class III): Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg, 30 tablets, Rx only, Manufactured for: Esperion Therapeutics, Inc,…

Watch this company

Alerts for recalls, exits, and new registrations.

Facility locations, FDA inspections, and parent-company mapping are on the roadmap. Name variants reported to FDA under different spellings are merged into this profile; figures cover the entity across all its filing names.